Back to top
more

Merck & Co. (MRK)

(Delayed Data from NYSE)

$102.32 USD

102.32
17,409,897

-2.51 (-2.39%)

Updated Oct 31, 2024 04:00 PM ET

After-Market: $102.65 +0.33 (0.32%) 7:58 PM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy24.10%
2Buy17.80%
3Hold9.50%
4Sell2.70%
5Strong Sell2.70%
S&P50011.20%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

3-Hold of 5     3    

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

Value Score A
Growth Score A
Momentum Score A
VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

B Value C Growth F Momentum C VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

Top 21% (53 out of 251)

Industry: Large Cap Pharmaceuticals

Better trading starts here.

Zacks News

Immutep (IMMP) Surges 65% on Upbeat Lung Cancer Study Data

A mid-stage study data shows that Immutep's (IMMP) lead candidate as a combination therapy in first-line NSCLC achieved better-than-expected overall survival results.

Here's Why Merck (MRK) Stock Has Outperformed Industry YTD

Strong sales of key products like Keytruda and Gardasil and positive pipeline/regulatory developments should keep Merck's (MRK) stock afloat in 2023.

Corvus Pharma (CRVS) Stock Surges 69.2% in a Week: Here's Why

Shares of Corvus Pharma (CRVS) surge 69% this week after the company provided updates on its pipeline development in the first quarter of 2023 earnings release.

The Zacks Analyst Blog Highlights UnitedHealth Group, Merck, Texas Instruments, The TJX Companies and Johnson Controls International

UnitedHealth Group, Merck, Texas Instruments, The TJX Companies and Johnson Controls International are part of the Zacks top Analyst Blog.

Mark Vickery headshot

Top Research Reports for UnitedHealth Group, Merck & Texas Instruments

Today's Research Daily features new research reports on 16 major stocks, including UnitedHealth Group Incorporated (UNH), Merck & Co., Inc. (MRK) and Texas Instruments Incorporated (TXN).

Neena Mishra headshot

Biotech ETFs Pop on M&A Resurgence

2023 could be a year of heightened biotech dealmaking activity

Iovance (IOVA) Posts Narrower-Than-Expected Loss in Q1

Iovance (IOVA) reports Q1 earnings that beat our estimates. The company's acquisition of IL-2 product Proleukin is expected to close in second-quarter 2023.

Mirati (MRTX) Q1 Earnings & Revenues Beat Estimates, Stock Up

Mirati (MRTX) reports better-than-expected first-quarter results, wherein earnings and revenues beat estimates. The stock climbs 2% on Tuesday. Pipeline development is on track.

Corcept (CORT) Misses on Q1 Earnings, Revises 2023 Sales Guidance

Corcept (CORT) first-quarter earnings miss estimates, while revenues beat the same. The company gives updates on its pipelines and raises revenue guidance for 2023.

Moderna (MRNA) Q1 Earnings & Sales Top Estimates, Stock Up 2%

Moderna (MRNA) beats expectations for both earnings and sales. The company posts higher-than-expected product sales from its COVID vaccine

Here is What to Know Beyond Why Merck & Co., Inc. (MRK) is a Trending Stock

Recently, Zacks.com users have been paying close attention to Merck (MRK). This makes it worthwhile to examine what the stock has in store.

Kinjel Shah headshot

Pharma Stock Roundup: MRK & Others Post Q1 Results, LLY Drug Shines in Obesity Study

Merck (MRK), Eli Lilly (LLY), AstraZeneca (AZN) and others report first-quarter results. J&J (JNJ) provides an update on the IPO of its Consumer Health segment, Kenvue.

Seagen's (SGEN) Q1 Earnings and Revenues Miss Expectations

Seagen (SGEN) reports worse-than-expected results in the first quarter of 2023, missing both earnings and sales estimates.

Company News for Apr 28, 2023

Companies In The News Are: MA, MRK, SO, NOC.

Moderna (MRNA) to Report Q1 Earnings: Will It Beat Estimates?

Investors focus will likely be on Moderna's (MRNA) pipeline, especially its late-stage pipeline candidates, when it reports first-quarter earnings.

Merck (MRK) Beats on Q1 Earnings and Sales, Ups 2023 View

Merck (MRK) beats Q1 estimates for earnings and sales. It raises its 2023 guidance. Stock rises in pre-market.

AstraZeneca (AZN) Q1 Earnings Beat, COVID Products Hurt Sales

AstraZeneca (AZN) beats first-quarter estimates for earnings while missing the same for sales. The company reaffirms its 2023 guidance.

Merck (MRK) Surpasses Q1 Earnings and Revenue Estimates

Merck (MRK) delivered earnings and revenue surprises of 4.48% and 4.65%, respectively, for the quarter ended March 2023. Do the numbers hold clues to what lies ahead for the stock?

Mark Vickery headshot

Markets Continue Steady Slide; META, EBAY Beat Q1 Earnings

Except the Nasdaq, which snapped a two-day losing streak and was the only major index in the green all day.

Ahan Chakraborty headshot

Drug/Biotech Stocks' Q1 Earnings Due Apr 27: LLY, ABBV & More

Let's look at the five biotech/pharma companies slated to release quarterly results on Apr 27.

Andrew Rocco headshot

Healthcare: An Essential Sector (3 Stocks to Buy Ahead of Earnings)

Healthcare stocks are an excellent place to park your money in the current market environment. Due to it's necessity, the sector tends to due well in any economy.

Pfizer (PFE) Expected to Beat Earnings Estimates: What to Know Ahead of Q1 Release

Pfizer (PFE) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

AstraZeneca (AZN) to Report Q1 Earnings: What's in the Cards?

Higher sales of AstraZeneca's (AZN) key medicines, Lynparza, Tagrisso, Imfinzi and Farxiga are expected to have driven sales, partially offset by lower sales of legacy drugs.

Zacks Investment Ideas feature highlights: Nasdaq 100 ETF, Dexcom, Merck, Intuitive Surgical and SPDR S&P Regional Bank ETF

Nasdaq 100 ETF, Dexcom, Merck, Intuitive Surgical and SPDR S&P Regional Bank ETF have been highlighted in this Investment Ideas article.